Editorial board

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

Retrieved on: 
Tuesday, February 20, 2024
Organic chemistry, Therapy, Bachelor of Science, Cancer, Alnylam Pharmaceuticals, Lakehead University, Senior, Enzyme, Doctor of Philosophy, Gene editing, Biotechnology, SAB, McGill University, Biocatalysis, Research and development, ANA, ECO, Masad, International Society, Oligonucleotide, Codexis, RNA, Nucleic acid, Central Waqf Council, Patient, Texas A&M University, About us, Infection, Editorial board, Publication, Development, Laboratory, Masad Damha, Management

This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Key Points: 
  • This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.
  • “We are thrilled to have Masad and Jim lend their decades of experience in oligonucleotide research and development to our Strategic Advisory Board,” said Stefan Lutz, PhD, Senior Vice President of Research at Codexis.
  • Dr. Damha is a co-founder of Anagenis, Inc., a start-up with proprietary antisense technologies (ANA and FANA).
  • Presently, Dr. Lalonde serves as Chairman of the Board of Directors at Willow Biosciences and as a Scientific Advisory Board member at Bota Biosciences, bitBiome, Curie Co. and Invizyne.

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Retrieved on: 
Wednesday, February 14, 2024
Opus, Drug development, University, IPO, Biomedicine, Vanderbilt University Medical Center, Biomedical engineering, Pharmacology, Genetics, American Diabetes Association, ARVO, Principal, NIH, Bank, Business development, Diabetic retinopathy, Therapy, Biomarker, Journal, Retina, Vanderbilt University, Biology, Discovery Medicine, Indiana University, OCUP, Roche, Visual impairment, Business, Diabetes, Paratriathlon, Economics, IND, Bank of America, Intelligence, FDA, Fortress Biotech, Doctor of Philosophy, Genentech, Insilico Medicine, Patient, Science, Editorial board, Citigroup, Pharmaceutical industry

FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Key Points: 
  • The team is now set and focused on executing our phase 3 program to turn our science into a reality for patients suffering from diabetic retinopathy, the leading cause of blindness in America.
  • I'm excited to work alongside such a talented team and together to take on significant unmet medical needs with compelling science.”
    Dr. Jayagopal added, “I am excited to join the talented Ocuphire team that has a successful track record in drug development and execution.
  • Prior to joining Ocuphire, he served as the Chief Scientific Officer of Opus Genetics.
  • In this role he had scientific and clinical leadership responsibility for Opus’ retinal gene therapy portfolio, including management of discovery, manufacturing, nonclinical development, and clinical development functions.

US-based Global Journals publishes Reltime's innovation on the use of 5G Handsets as Nodes in Layer-1 Blockchain

Retrieved on: 
Wednesday, February 14, 2024
Philosophy, Sociology, Research, LINK, Web3, Communication, Medicine, Knowledge, Funding of science, Telecommunications, Science, Editorial board, Publication, Telecom, App Store (iOS/iPadOS), Cryptocurrency

Reltime is pleased to announce that this innovation initiative has been recognised by Massachusetts based Global Journals, which has published this research work ( LINK ), authored by Frode van der Laak, CTO & Co-Founder of Reltime.

Key Points: 
  • Reltime is pleased to announce that this innovation initiative has been recognised by Massachusetts based Global Journals, which has published this research work ( LINK ), authored by Frode van der Laak, CTO & Co-Founder of Reltime.
  • Global Journals' publications are subjected to a rigorous evaluation with an exceptional review process from its Editorial Board.
  • Our initiative to integrate 5G handsets as nodes in Reltime's Layer-1 Blockchain is more than just an innovation, it's a commitment to pushing the boundaries of what's possible.
  • Reltime's cutting-edge integration, once completed, will deliver unprecedented speed, security, and efficiency, driving significant synergies between blockchain and 5G handsets and telecommunications technologies.

Six New Directors Join Board of Operation Underground Railroad

Retrieved on: 
Tuesday, February 6, 2024
Public Policy, Government, Law Enforcement, Emergency Services, Other Policy Issues, NGO, Policy, Disability, College, Research, Child, Recreation, Athlete, Applied science, Marketing, Speech, United States Army, Operation Underground Railroad, Editorial board, Organization development, Abuse, Quality of life, Risk, Journal, Lehigh University, Acquisition, Volunteering, Empowerment, Workforce, Organization, Management

Operation Underground Railroad (“O.U.R.”), a leading non-profit organization dedicated to combating human trafficking, today announced that six accomplished professionals have joined its board of directors.

Key Points: 
  • Operation Underground Railroad (“O.U.R.”), a leading non-profit organization dedicated to combating human trafficking, today announced that six accomplished professionals have joined its board of directors.
  • “It is a privilege to serve on O.U.R.’s board with my fellow directors, who bring a wealth of experience, expertise, and passionate commitment to O.U.R.’s mission of rescuing and supporting victims of trafficking and exploitation,” said Board Chairman Sean Vassilaros.
  • Through her commitment and expertise, she is an essential figure in protecting children from trafficking and other online dangers.
  • Sean is the co-Founder and Chief Executive Officer of KANNY, an innovative software company in the HR Tech space.

Kirstjen Nielsen Appointed to the National Defense University Foundation Board

Retrieved on: 
Monday, December 4, 2023
Georgetown University, National Defense University, Policy, Editorial board, Virginia School for Girls, Foreign Service, Student, Faculty, NDU, University, Service, Non-governmental organization, Lighthouse, The Security Institute, Central Waqf Council, Management

WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- The National Defense University (NDU) Foundation announced the appointment of Kirstjen M. Nielsen to the NDU Foundation Board of Directors.

Key Points: 
  • WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- The National Defense University (NDU) Foundation announced the appointment of Kirstjen M. Nielsen to the NDU Foundation Board of Directors.
  • "Secretary Nielsen's deep experience stands at the crossroads of policy, strategy and operations," said Rob Spring, NDU Foundation Board Chairman.
  • "I am proud to join the Board in ensuring the continued tradition of excellence and mission success of the National Defense University."
  • She serves on the Board of Advisors for the Global and National Security Institute at the University of South Florida, as a Board Member of the Global Resilience Federation, and as an Editorial Board member of Homeland Security Today.

American Journal of Endocannabinoid Medicine (AJEM) Emerges as Premier Resource for Healthcare Professionals to Explore the Endocannabinoid System

Retrieved on: 
Monday, October 30, 2023
Research, Cannabis, Other Health, Alternative Medicine, Health, Pharmaceutical, General Health, Science, Natural Resources, Online, Knowledge, Health care, ECS, Physician, Medicine, News, Material, Editorial board, Education, American Journal, Medical device, Nursing

The medical community's understanding of the endocannabinoid system (ECS) has been greatly enhanced with the launch of the American Journal of Endocannabinoid Medicine (AJEM) .

Key Points: 
  • The medical community's understanding of the endocannabinoid system (ECS) has been greatly enhanced with the launch of the American Journal of Endocannabinoid Medicine (AJEM) .
  • AJEM has emerged as the leading resource for healthcare professionals seeking comprehensive and high-level insights into the intricate world of the ECS.
  • Healthcare providers, particularly physicians and medical professionals, are increasingly recognizing the significance of the endocannabinoid system in human health.
  • The American Journal of Endocannabinoid Medicine (AJEM) is the leading online platform dedicated to educating healthcare professionals on medicines that engage with the endocannabinoid system (ECS).

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

Retrieved on: 
Thursday, September 14, 2023
Commissioner, The Lancet, Investment-specific technological progress, Society, PNAS, MCMC, PI, CAB, IAC, Nivolumab, American Society of Clinical Oncology, Shanghai Jiao Tong University, Oncology, Editorial board, Journal of Thoracic Oncology, Clinical Cancer Research, Lung cancer, Tel Aviv University, Doctor of Philosophy, Committee, ASCO, JAMA Oncology, Melvin Mooney Distinguished Technology Award, Journal, MD, SAN, EGFR, Drug discovery, CSCO, Editor-in-chief, Shanghai Chest Hospital, Therapy, MD Anderson Cancer Center, Pharmaceutical industry, Science, Bevacizumab, Savolitinib, Tislelizumab

SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).

Key Points: 
  • SAN DIEGO, Sept. 14, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that Professor Shun Lu, an internationally renowned oncologist and professor at Shanghai Jiao Tong University Chest Hospital, has joined the Company's Clinical Advisory Board (CAB).
  • "We are excited to have Professor Lu joining our Clinical Advisory Board," said Rita Laeufle, MD, PhD, Phanes' Chief Medical Officer. "
  • Professor Lu is a leading clinician-scientist in the field of lung cancer.
  • He also served on the International Affairs Committee (IAC) of American Clinical Oncology Society (2008-2011) and MCMC Working Group (2008-2016).

Achieve named one of Arizona's 'Most Admired Companies' for third consecutive year by Az Business magazine, BestCompaniesAZ

Retrieved on: 
Wednesday, September 6, 2023
Linda, Social responsibility, Workplace, Built to Last: Successful Habits of Visionary Companies, AZ Business Magazine, American City Business Journals, AZ, SAN, Editorial board, Management

SAN MATEO, Calif., Sept. 6, 2023 /PRNewswire/ -- Achieve, the leader in digital personal finance, announced today it has been recognized as one of Arizona's Most Admired Companies of 2023 by Az Business magazine and BestCompaniesAZ. This is the third consecutive year Achieve has been named to the list.

Key Points: 
  • This is the third consecutive year Achieve has been named to the list.
  • The award honors employers that excel in customer opinion, innovation, leadership excellence, social responsibility and workplace culture.
  • In January, it was named to Az Business magazine's AZ Big 100 List.
  • "Achieve is honored to once again be recognized as one of Arizona's most admired companies," said Achieve Executive Vice President of Human Resources Linda Luman.

Nexcella Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, Patient, MD, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, MD–PhD, Pharmaceutical industry

Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.

Key Points: 
  • Dr. Lentzsch joins the Nexcella Scientific Advisory Board with decades of experience treating patients with AL Amyloidosis and multiple myeloma and serving as a principal investigator on clinical trials for novel agents.
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • I am thrilled to join the Nexcella Scientific Advisory Board.”
    “We are delighted to be joined by Dr. Lentzsch on the Nexcella Scientific Advisory Board,” stated Ilya Rachman, MD PhD Executive Chairman of Nexcella.

Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board

Retrieved on: 
Friday, September 1, 2023
Columbia University, Journal of Clinical Oncology, Society, Hematology, Multiple myeloma, Physician, AL amyloidosis, Editorial board, IMS, NewYork-Presbyterian Hospital, SOHO, AstraZeneca, JCO, Trial of the century, Medicine, Journal, Committee, AL, MD, Patient, Amyloidosis, Surgeon, Education, LOS, Editor-in-chief, Pharmaceutical industry

Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.

Key Points: 
  • Dr. Lentzsch brings extensive experience focused on new therapeutic agents across AL Amyloidosis and multiple myeloma to Nexcella.
  • “I have been fortunate to lead efforts to conduct clinical trials resulting in new treatment options for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Lentzsch.
  • “Nexcella is developing an autologous CAR-T with clinical results that are encouraging in relapsed AL Amyloidosis and relapsed multiple myeloma.
  • She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries.